High Cardiac Output States: Causes, Pathophysiology, and Clinical Implications

A high cardiac output state exists when resting cardiac output exceeds 8 L/min or cardiac index surpasses 4.0 L/min/m² in the absence of physical exertion. The underlying hemodynamic mechanism in virtually all high-output conditions involves reduced systemic vascular resistance (SVR), which decreases afterload and facilitates greater ventricular ejection. The cardiovascular system compensates for the reduced vascular tone through neurohormonal activation — increased sympathetic tone raises heart rate and contractility, while expanded blood volume augments preload — producing the characteristic hyperdynamic circulatory pattern.

The clinical presentation of high cardiac output states often includes a wide pulse pressure (elevated systolic with low diastolic blood pressure), bounding peripheral pulses, warm flushed extremities, and a hyperdynamic precordium with systolic flow murmurs. These findings contrast sharply with low cardiac output states, where extremities are cool and peripheral pulses are thready. Tachycardia is common, reflecting sympathetic activation in response to reduced SVR. On echocardiography, the left ventricle may appear hyperdynamic with supranormal ejection fraction and vigorous wall motion.

The distinction between physiological and pathological high cardiac output is clinically important. Physiological elevations (exercise, pregnancy, anxiety) are transient and self-limited, with the cardiovascular system fully compensating without adverse sequelae. Pathological high-output states, by contrast, place chronic volume and pressure overload on the heart, leading to progressive ventricular dilation, neurohormonal activation, and eventually the syndrome of high-output heart failure if the underlying cause is not addressed. Early identification and treatment of the underlying etiology is the cornerstone of management.

Sepsis and systemic inflammatory response syndrome (SIRS) are among the most common causes of pathological high cardiac output in the critical care setting. Inflammatory mediators including nitric oxide, prostaglandins, and cytokines produce profound vasodilation and reduced SVR, triggering compensatory increases in heart rate and stroke volume. In the early (warm) phase of septic shock, cardiac output is elevated despite tissue hypoperfusion — a paradox that results from distributive microvascular dysfunction and impaired oxygen extraction rather than inadequate flow. This distinguishes distributive shock from cardiogenic shock, where low flow is the primary problem.

Thyrotoxicosis (hyperthyroidism) increases cardiac output through multiple mechanisms: thyroid hormones directly increase myocardial contractility and heart rate, reduce SVR by promoting peripheral vasodilation, and increase metabolic rate, raising total body oxygen consumption. Cardiac output may increase by 50–300% above normal in severe thyrotoxicosis. Atrial fibrillation occurs in 10–25% of hyperthyroid patients and can further compound the hemodynamic burden. Severe anemia (hemoglobin < 7 g/dL) triggers compensatory increases in cardiac output to maintain tissue oxygen delivery despite reduced oxygen-carrying capacity, with CO rising in inverse proportion to hemoglobin concentration.

Arteriovenous (AV) fistulae — whether surgically created for hemodialysis access, congenital, or acquired (post-traumatic, hepatic) — shunt blood from the arterial to venous circulation, bypassing the capillary bed and effectively reducing SVR. Large AV fistulae with flows exceeding 1.5–2.0 L/min can produce significant increases in cardiac output. Other causes include Paget disease of bone (increased blood flow through hypervascular pagetic bone), beriberi (thiamine deficiency causing peripheral vasodilation and myocardial dysfunction), hepatic cirrhosis (splanchnic vasodilation and portosystemic shunting), and morbid obesity (increased metabolic demands and expanded blood volume).

High-output heart failure (HOHF) is the paradoxical condition in which patients develop the clinical syndrome of heart failure — dyspnea, edema, elevated jugular venous pressure, pulmonary congestion — despite having a cardiac output that exceeds normal resting values. The pathophysiology involves chronic volume overload and neurohormonal activation triggered by the underlying high-output state. Persistent stimulation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system leads to sodium and water retention, plasma volume expansion, and progressive cardiac chamber dilation.

The key distinguishing feature of HOHF is that the heart is not intrinsically failing in the traditional sense — myocardial contractility may be preserved or even supranormal initially. Rather, the cardiac output, though elevated, is insufficient relative to the abnormally high metabolic demands or the volume of blood being shunted through low-resistance pathways. Over time, chronic volume overload leads to eccentric ventricular hypertrophy, progressive ventricular dilation, functional mitral and tricuspid regurgitation, and eventually biventricular systolic dysfunction. At this late stage, the cardiac output may fall into the normal or even low range despite the ongoing high-output stimulus.

HOHF accounts for an estimated 3–6% of all heart failure hospitalizations and is frequently underdiagnosed because clinicians may not consider heart failure in a patient with warm extremities, bounding pulses, and a hyperdynamic precordium. The diagnosis requires hemodynamic documentation of elevated cardiac output or index in the setting of clinical heart failure and elevated filling pressures. Right heart catheterization demonstrating high CO/CI with elevated PCWP and right atrial pressure confirms the diagnosis. Treatment is directed primarily at the underlying cause rather than conventional heart failure therapies, which may be ineffective or harmful.

Diagnosing high cardiac output states requires a high index of clinical suspicion, particularly in patients presenting with heart failure symptoms and warm, well-perfused extremities. The initial evaluation includes echocardiography (which may reveal hyperdynamic LV function, chamber dilation, and elevated estimated pulmonary pressures), complete blood count (to identify anemia), thyroid function tests, and assessment for AV fistulae or shunts. Right heart catheterization provides definitive hemodynamic characterization, documenting elevated CO/CI, reduced SVR, and elevated filling pressures in HOHF.

Management of high cardiac output states is directed primarily at identifying and treating the underlying etiology. For sepsis, source control and appropriate antimicrobial therapy are paramount. Thyrotoxicosis requires antithyroid medications (methimazole, propylthiouracil), beta-blockers to control heart rate, and definitive therapy (radioactive iodine or thyroidectomy). Severe anemia necessitates transfusion or treatment of the underlying cause (iron deficiency, bleeding). Large AV fistulae causing heart failure may require surgical ligation, endovascular embolization, or revision to reduce fistula flow. In Paget disease, bisphosphonates reduce bone turnover and vascularity.

Conventional heart failure medications must be used judiciously in HOHF. Diuretics can alleviate volume overload and congestive symptoms but may be counterproductive if the high-output state depends on adequate preload. Beta-blockers are beneficial in thyrotoxicosis-related HOHF but may be harmful in other etiologies where compensatory tachycardia is maintaining cardiac output. ACE inhibitors and ARBs may help counteract neurohormonal activation but could worsen hypotension in patients with already low SVR. A tailored approach guided by hemodynamic monitoring and directed at the specific underlying cause produces the best outcomes.